Controversial clinical evidence (fractures, non-union, and osteonecrosis); Preliminary knowledge and few low quality reports; Positive findings in many studies, but mixed efficacy and adverse events in overall literature; Unclear conclusions (heterogeneity of studies: different BMPs, doses and delivery method for each bone pathology). This evidence concerns the gene CLN5 and osteonecrosis.